Patients with central nervous system (CNS) lymphomas have a poor prognosis. Chimeric antigen receptor-modified (CAR) T cells have shown remarkable efficacy for B-cell non-Hodgkin's lymphoma. However, few studies have reported the effects of CAR T cells in the treatment of CNS lymphoma, and the duration of remission is short. In this study, seven CNS lymphoma patients (six patients with secondary CNS lymphomas and one patient with primary CNS lymphoma) were treated with CD19 or CD20 CAR T cell therapy, and the clinical efficacy and toxicity profiles were evaluated. All patients responded to CAR T cell therapy. Four patients achieved complete remission (CR), while three demonstrated partial remission. We also found that either CD19 or CD20 CAR T cells could be detected in the cerebrospinal fluid of four patients. The median progression-free survival and median overall survival were not assessed. The median duration of CR was 22.4 months. Five patients (5/7) in this cohort received combination therapy (bridging with autologous hematopoietic stem cell transplantation and programmed death-1 inhibitor for maintenance treatment) and three (3/7) received CAR T cell therapy as soon as possible after the relapse of CNS lymphoma. This could help explain why these patients achieved long-term remission. After a median follow-up of 10.4 months, three patients demonstrated disease progression, and the antigen loss of CD20 was confirmed as the reason for relapse in one patient. The results of this study suggest that CD19 or CD20 CAR T cells are effective against CNS lymphoma. This research was registered at http://www.chictr.org.cn (No. ChiCTR2000036350).
Get full access to this article
View all access options for this article.
References
1.
BoehmeV, SchmitzN, ZeynalovaS, et al.CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 2009; 113:3896–3902.
2.
FeugierP, VirionJM, TillyH, et al.Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol, 2004; 15:129–133.
3.
BernsteinSH, UngerJM, LeblancM, et al.Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group. J Clin Oncol, 2009; 27:114–119.
4.
El-GalalyTC, CheahCY, BendtsenMD, et al.Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer, 2018; 93:57–68.
5.
BoehmeV, ZeynalovaS, KloessM, et al.Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol, 2007; 18:149–157.
6.
SchmitzN, ZeynalovaS, GlassB, et al.CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol, 2012; 23:1267–1273.
7.
BrombergJEC, IssaS, BakuninaK, et al.Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol, 2019; 20:216–228.
8.
SoussainC, Hoang-XuanK, TaillandierL, et al.Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol, 2008; 26:2512–2518.
9.
CoteGM, HochbergEP, MuzikanskyA, et al.Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 2012; 18:76–83.
10.
SoussainC, ChoquetS, FourmeE, et al.Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica, 2012; 97:1751–1756.
11.
FerreriAJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematol Am Soc Hematol Educ Program, 2017; 2017:565–577.
12.
NeelapuSS, LockeFL, BartlettNL, et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med, 2017; 377:2531–2544.
13.
LockeFL, GhobadiA, JacobsonCA, et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol, 2019; 20:31–42.
14.
SchusterSJ, BishopMR, TamCS, et al.Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med, 2019; 380:45–56.
15.
LockeFL, NeelapuSS, BartlettNL, et al.Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther, 2017; 25:285–295.
16.
AbramsonJS, McGreeB, NoyesS, et al.Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med, 2017; 377:783–784.
17.
GhafouriS, TimmermanJ, LarsonS, et al.Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?. Bone Marrow Transplant, 2021; 56:974–977.
18.
SiddiqiT, WangX, BlanchardMS, et al.CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv, 2021; 5:4059–4063.
19.
LiT, ZhaoL, ZhangY, et al.CAR T-cell therapy is effective but not long-lasting in B-cell lymphoma of the brain. Front Oncol, 2020; 10:1306.
20.
FrigaultMJ, DietrichJ, Martinez-LageM, et al.Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood, 2019; 134:860–866.
21.
SauterCS, SenechalB, RivièreI, et al.CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood, 2019; 134:626–635.
22.
ChongEA, MelenhorstJJ, LaceySF, et al.PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood, 2017; 129:1039–1041.
23.
JohnLB, KershawMH, DarcyPK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology, 2013; 2:e26286.
24.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 1993; 329:987–994.
25.
ZhangY, LiJ, LouX, et al.A prospective investigation of bispecific CD19/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Front Oncol, 2021; 11: 664421.
26.
InghamAC, KielsenK, MordhorstH, et al.Microbiota long-term dynamics and prediction of acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Microbiome, 2021; 9:148.
27.
SilvestreOM, GonçalvesA, NadruzWJr.,et al.Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study. Eur J Heart Fail, 2017; 19:340–347.
28.
LaustsenA, BakRO, KrappC, et al.Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function. Nat Commun, 2018; 9:3525.
29.
LeeDW, SantomassoBD, LockeFL, et al.ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant, 2019; 25:625–638.
30.
NeelapuSS, TummalaS, KebriaeiP, et al.Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol, 2018; 15:47–62.
31.
ChesonBD, FisherRI, BarringtonSF, et al.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 2014; 32:3059–3068.
32.
WuJ, MengF, CaoY, et al.Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer J, 2021; 11:131.
33.
NeelapuSS, DickinsonM, UlricksonML, et al.Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Blood, 2020; 136(Supplement 1):49.
34.
KochenderferJN, DudleyME, KassimSH, et al.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol, 2015; 33:540–549.
35.
ShahNN, FryTJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol, 2019; 16:372–385.
36.
SangW, ShiM, YangJ, et al.Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med, 2020; 9:5827–5838.
37.
MartyniszynA, KrahlAC, AndréMC, et al.CD20-CD19 bispecific CAR T cells for the treatment of B-cell malignancies. Hum Gene Ther, 2017; 28:1147–1157.
38.
ShahNN, JohnsonBD, SchneiderD, et al.Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med, 2020; 26:1569–1575.
39.
TongC, ZhangY, LiuY, et al.Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood, 2020; 136:1632–1644.
40.
ShiY, HanY, YangJ, et al.Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res, 2019; 31:152–161.
41.
BentoL, Díaz-LópezA, BarrancoG, et al.New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Br J Haematol, 2020; 188:888–897.
42.
VercellinoL, Di BlasiR, KanounS, et al.Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv, 2020; 4:5607–5615.
43.
LockeFL, RossiJM, NeelapuSS, et al.Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv, 2020; 4:4898–4911.
44.
JacobsonCA, HunterBD, ReddR, et al.Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol, 2020; 38:3095–3106.
45.
PinnixCC, GuntherJR, DabajaBS, et al.Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv, 2020; 4:2871–2883.
46.
LyuC, CuiR, WangJ, et al.Intensive debulking chemotherapy improves the short-term and long-term efficacy of anti-CD19-CAR-T in refractory/relapsed DLBCL with high tumor bulk. Front Oncol, 2021; 11:706087.
47.
IsodaA, KairaK, IwashinaM, et al.Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci, 2014; 105:1496–1502.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
